Condition
Hematologic Disease and Disorders clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Hematologic Disease and Disorders clinical trials that are recruiting, at sites in 4 countries (most in United States (2), Australia (2), China (1)). By phase: Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest Hematologic Disease and Disorders clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| HSCT outcomes in children at Ramathibodi Hospital | — | Ratchathewi, Bangkok | Recruiting | Oct 5, 2026 |
| Reconstruction kinetics of γδ T cells after an unrelated cord blood transplant | — | Hefei, Anhui | Recruiting | Aug 24, 2026 |
| Clonal haematopoiesis assessment and long-term monitoring for prevention and care | — | Canberra, Australian Capital Territory | Recruiting | Dec 31, 2025 |
| KLN-1010 gene therapy for relapsed or refractory multiple myeloma | Phase 1 | Duarte, California and 10 other locations | Recruiting | Jul 20, 2025 |
| Early tacrolimus in HLA-mismatched haploidentical blood stem-cell transplant with post-transplant cyclophosphamide | Phase 2 | Atlanta, Georgia | Recruiting | Feb 14, 2025 |
All recruiting trials (5)
-
HSCT outcomes in children at Ramathibodi Hospital
This study tests how hematopoietic stem cell transplantation works in pediatric patients with blood diseases, cancers, and other conditions at Ramathibodi Hospital.
-
Reconstruction kinetics of γδ T cells after an unrelated cord blood transplant
This study tests how γδ T cells recover after an unrelated cord blood transplant and whether recovery patterns relate to outcomes like graft-versus-host disease, relapse, and survival.
-
Clonal haematopoiesis assessment and long-term monitoring for prevention and care
This project will follow people aged 55 and older who have clonal haematopoiesis or unexplained low blood counts to see how their blood changes over time and whether they develop heart disease or blood cancers.
-
KLN-1010 gene therapy for relapsed or refractory multiple myeloma
This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.
-
Early tacrolimus in HLA-mismatched haploidentical blood stem-cell transplant with post-transplant cyclophosphamide
This trial tests whether starting tacrolimus earlier, together with post-transplant cyclophosphamide and mycophenolate, can reduce cytokine release syndrome in people receiving HLA-mismatched haploidentical peripheral blood stem-cell transplants.
Related topics
Quick answers
How many Hematologic Disease and Disorders clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (2 trials), Australia (2 trials), China (1 trial), Thailand (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.